会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS
    • 1,2,4-异噻唑衍生物作为VASOPRESSIN ANTAGONISTS
    • WO2006123242A1
    • 2006-11-23
    • PCT/IB2006/001442
    • 2006-05-08
    • PFIZER LIMITEDBRYANS, Justin, StephenJOHNSON, Patrick, StephenROBERTS, Lee, RichardRYCKMANS, Thomas
    • BRYANS, Justin, StephenJOHNSON, Patrick, StephenROBERTS, Lee, RichardRYCKMANS, Thomas
    • C07D403/04C07D471/04C07D491/10C07D471/10C07D403/14C07D401/04C07D487/04C07D498/04A61K31/4196A61P15/00A61P9/00
    • C07D471/04C07D401/04C07D403/04C07D403/14C07D471/10C07D487/04C07D491/10C07D498/04
    • Compounds of formula (I), or a pharmaceutically acceptable salt, solvate, ester or amide thereof, wherein R 1 represents [CH 2 ] n -R 2 ; R 2 represents H, C 1-6 alkyloxy or Het; n represents a number selected from 0 to 6; Het represents an unsaturated heterocycle of 5 or 6 atoms containing one or more heteroatoms selected from O, N, and S; R 3 represents halo; Ring A represents a 4 to 7 membered, saturated, partially saturated, or unsaturated heterocycle containing one or more heteroatoms selected from O, N, and S; Ring B represents a saturated, partially saturated, or unsaturated heterocycle of from 3 to 8 atoms containing one or more heteroatoms selected from O, N, and S, or Ring B represents a saturated or unsaturated carbocyclic ring of from 3 to 8 atoms; Ring B is optionally fused to an aryl ring and is optionally substituted with one or more groups independently selected from R 4 ; Ring A and Ring B share at least one atom; R 4 represents oxo, [CH 2 ] m -R 5 , or CH-R 6 R 7 ; R 5 represents H, OH, C 1-6 alkyloxy, COOH, or CONR 8 R 9 ; m represents a number selected from 0 or 1 ; and R 6 , R 7 , R 8 and R 9 independently represent H or C 1-6 alkyl; are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhoea.
    • 式(I)化合物或其药学上可接受的盐,溶剂合物,酯或酰胺,其中R 1表示[CH 2 N] -R 2 ; R 2表示H,C 1-6烷氧基或Het; n表示选自0〜6的数; Het表示含有一个或多个选自O,N和S的杂原子的5或6个原子的不饱和杂环; R 3表示卤素; 环A表示含有一个或多个选自O,N和S的杂原子的4至7元饱和的,部分饱和的或不饱和的杂环; 环B表示含有一个或多个选自O,N和S的杂原子的3至8个原子的饱和,部分饱和或不饱和杂环,或环B表示3至8个原子的饱和或不饱和碳环; 环B任选地与芳环稠合并且任选地被一个或多个独立地选自R 4的基团取代; 环A和环B共享至少一个原子; R 4表示氧代,[CH 2 CH 2] m -R 5或CH-R 6 - [R 7 ; R 5表示H,OH,C 1-6烷氧基,COOH或CONR 8 R 9; m表示选自0或1的数字; 且R 6,R 7,R 8和R 9独立地表示H或C 1〜 6烷基; 可用于治疗指示V1a拮抗剂的疾病,特别是痛经。
    • 5. 发明申请
    • 3-HETEROCYCLYL-4-PHENYL-TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN V1A RECEPTOR
    • 作为VASOPRESSIN V1A受体的抑制剂的3-环己基-4-苯基 - 三唑衍生物
    • WO2005105779A1
    • 2005-11-10
    • PCT/IB2005/001062
    • 2005-04-18
    • PFIZER LIMITEDPFIZER INC.BRYANS, Justin, StephenJOHNSON, Patrick, StephenRYCKMANS, ThomasSTOBIE, Alan
    • BRYANS, Justin, StephenJOHNSON, Patrick, StephenRYCKMANS, ThomasSTOBIE, Alan
    • C07D401/04
    • C07D401/04C07D401/12C07D401/14C07D403/04C07D403/14
    • Compounds of formula (I): or a pharmaceutically acceptable derivative thereof, wherein R represents C 1-6 alkyl (optionally substituted by C 1-6 alkyloxy or Het) or C 1-6 alkyloxy; R 1 and R 2 independently represent hydrogen, halo or C 1-6 alkyl, ring A represents Het 1 ; X represents O or NR 3 ; R 3 represents hydrogen or C 1-6 alkyl; ring B represents a phenyl group or Het 2 , either of which may be optionally substituted with one or more groups selected from halo, CN, C 1-6 alkyloxy, CF 3 , C 1-6 alkyl, NH 2 and NO 2 ; Het and Het 1 independently represent a 5- or 6-membered saturated, partially unsaturated or aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atoms and 1 or 2 nitrogen atoms are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis) mittlesmerchz, preclampsia, premature ejaculation, premature (preterm) labour and Raynaud’s disease.
    • 式(I)化合物或其药学上可接受的衍生物,其中R表示C 1-6烷基(任选被C 1-6烷氧基或Het取代)或C 1-6烷氧基; R 1和R 2独立地表示氢,卤素或C 1-6烷基,环A表示Het 1; X表示O或NR 3; R 3表示氢或C 1-6烷基; 环B表示苯基或Het 2,其任一个可以任选被一个或多个选自卤素,CN,C 1-6烷氧基,CF 3,C 1-6烷基,NH 2和NO 2的基团取代; Het和Het 1独立地表示包含(a)1至4个氮原子,(b)一个氧或一个硫原子或(c)1个氧原子的5或6元饱和,部分不饱和或芳族杂环基 或1个硫原子和1或2个氮原子可用于治疗焦虑,心血管疾病(包括心绞痛,动脉粥样硬化,高血压,心力衰竭,水肿,高钠血症),痛经(原发性和继发性),子宫内膜异位症,呕吐(包括晕车病) 子宫内生长迟缓,炎症(包括类风湿关节炎)手足牢,先兆子痫,早泄,早产(早产)劳动和雷诺氏病。
    • 6. 发明申请
    • TRIAZOLE COMPOUNDS USEFUL IN THERAPY
    • 三唑化合物有用于治疗
    • WO2004074291A1
    • 2004-09-02
    • PCT/IB2004/000432
    • 2004-02-09
    • PFIZER LIMITEDPFIZER INC.BRYANS, Justin, StephenJOHNSON, Patrick, StephenRYCKMANS, ThomasSTOBIE, Alan
    • BRYANS, Justin, StephenJOHNSON, Patrick, StephenRYCKMANS, ThomasSTOBIE, Alan
    • C07D487/04
    • C07D401/04C07D413/14C07D487/04C07D513/04
    • A compound of formula (I), or a pharmaceutically acceptable derivative thereof, wherein V represents -(CH 2 ) d (O) e -, -CO-, or -CH(C 1-6 alkyl)-; W is -0-, -S(O) a , or -N(R 1 ')-R 1 represents H, C 1-6 alkyl, (CH 2 ) b COR 2 , CO(CH 2 ) b NR 2 R 3 , S0 2 R 2 , ( CH 2 ) c OR 2 , (CH 2 ) c ,NR 2 R 3 , or (CH 2 ) b het 1 ; het 1 represents a saturated or unsaturated heterocycle of from 3 to 8 atoms containing one or more heteroatoms selected from O, N, or S, optionally substituted with C 1-6 alkyl; X and Y independently represent H, C 1-6 alkyl, halogen, OH, CF 3 , OCF 3 , OR 4 ; Z represents -(CH 2 ) f (O) g , -CO- or -CH(C 1-6 alkyl)-; Ring A represents a 4-7 membered, saturated N-containing heterocycle, optionally substituted with OH, and in which optionally at least one ring N is substituted with O;Ring B represents phenyl or a 4-7 membered unsaturated N-containing heterocycle, optionally substituted with OH, halogen, CN, CONH 2 , CF 3 , OCF3, and in which optionally at least one ring N is substituted with O; R 2 and R 3 independently represent H, C 1-6 alkyl [optionally substituted with OH, halogen,N(C 1.6 alkyl) 2 , or C 1.6 alkyloxy], C 1.6 alkyloxy, N(C 1-6 alkyl) 2 , or [C 3-8 cycloalkyl]; or R 2 and R 3 , together with the nitrogen atom to which they are attached independently represent a heterocycle of from 3 to 8 atoms, optionally substituted with C 1-6 alkyl;R4 represents straight or branched C 1-6 alkyl, a and c independently represent 0, 1, or 2; b, e and g independently represent 0 or 1; d and f independently represent 1 or 2;are useful in the treatment of dysmenorrhoea.
    • 式(I)化合物或其药学上可接受的衍生物,其中V表示 - (CH 2)d(O)e - , - CO-或-CH(C 1-6烷基) - 。 W是-O - , - S(O)a或-N(R 1')-R 1表示H,C 1-6烷基,(CH 2)b -COR 2,CO(CH 2)b NR (CH 2)b CH 2,(CH 2)c,NR 2, het <1>表示3至8个原子的饱和或不饱和杂环,其含有一个或多个选自O,N或S的杂原子,任选被C 1-6烷基取代; X和Y独立地表示H,C 1-6烷基,卤素,OH,CF 3,OCF 3,OR 4; Z表示 - (CH 2)f(O)g,-CO-或-CH(C 1-6烷基) - ; 环A表示任选被OH取代的4-7元饱和的含N的杂环,并且其中任选地至少一个环被O取代;环B表示苯基或4-7元不饱和的含N的杂环, 任选地被OH,卤素,CN,CONH 2,CF 3,OCF 3取代,并且其中任选地至少一个环N被O取代; R 2和R 3独立地表示H,C 1-6烷基(任选被OH,卤素,N(C 1-6烷基)2或C 1-6烷氧基取代),C 1-6烷氧基,N(C 1-6 烷基)2或[C 3-8环烷基]; 或R 2和R 3与它们所连接的氮原子一起独立地表示3至8个原子的杂环,任选被C 1-6烷基取代; R 4表示直链或支链C 1-6 烷基,a和c独立地表示0,1或2; b,e和g独立地表示0或1; d和f独立地表示1或2;可用于治疗痛经。
    • 7. 发明申请
    • TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA
    • 三唑类化合物用于治疗脑损伤
    • WO2004037809A1
    • 2004-05-06
    • PCT/IB2003/004587
    • 2003-10-14
    • PFIZER LIMITEDPFIZER INC.ARMOUR, Robert, DuncanBAXTER, Andrew, DouglasBRYANS, Justin, StephenDACK, Kevin, NeilJOHNSON, Patrick, StephenLEWTHWAITE, Russell, AndrewNEWMAN, JulieRAWSON, David, JamesRYCKMANS, Thomas
    • ARMOUR, Robert, DuncanBAXTER, Andrew, DouglasBRYANS, Justin, StephenDACK, Kevin, NeilJOHNSON, Patrick, StephenLEWTHWAITE, Russell, AndrewNEWMAN, JulieRAWSON, David, JamesRYCKMANS, Thomas
    • C07D401/04
    • C07D401/04C07D401/06C07D401/12C07D401/14C07D403/12C07D405/14C07D413/04C07D413/06C07D413/14
    • A compound of formula (I), a pharmaceutically acceptable salt or solvate thereof, wherein R' represents C,-C6 alkyl, -(CH 2 ) c -[C 3 -C 8 cycloalkyl]-, -(CH 2 ) C -W or -(CH 2 ) C -Z-(CH 2 ) d W; W represents C 1 -C 6 alkyl, C 1 -C 6 alkyloxy, -C0 2 [C 1 -C 6 alkyl], -CONR 4 R 5 , an optionally substituted phenyl group, NR 4 R 5 , het 2 or het 3 ; Z represents O or S(O) g ; g represents 0, 1 or 2; R 2 represents a phenyl group, optionally fused to a 5- or 6- membered aryl or heterocyclic group which may contain one or more heteroatoms selected from N, O or S; the phenyl group and the optionally fused group being optionally substituted; Ring A represents a 4-, 5- or 6- membered saturated heterocyclic group containing at least one N; Ring B represents a phenyl group or het 1 , each group being optionally substituted; R 7 independently represents H 1 C 1 -C 6 alkyl, OR 3 , -(CH 2 ) e -R 3 or -(CH 2 ) f -O-(CH 2 ) e -R 3 ; at each occurrence R 3 independently represents H 1 C 1 -C 6 alkyl optionally substituted by Y, -(CH 2 ) g [C 3 -C 8 cycloalkyl], phenyl, benzyl, pyridyl or pyrimidyl; at each occurrence R 4 and R 5 independently represent H 1 C l -C 6 alkyl (optionally substituted with C l -C 6 alkyloxy), (CH 2 ) g C0 2 -[C 1 -C 6 alkyl], -S0 2 Me, -(CH 2 ) g [C 3 -C 8 cycloalkyl], S0 2 Me, phenyl, benzyl, pyridyl or pyrimidyl; or R 4 and R 5 together with the N atom to which they are attached represent a heterocyclic group of from 3 to 8 atoms; Y independently represents a phenyl group, NR 4 R 5 or het 4 , the phenyl group being optionally substituted; het 1 represents a 4-, 5- or 6- membered saturated, or unsaturated, heterocyclic group containing at least one N (but which may also contain one or more O or S atoms); het 2 and het 4 represent an optionally substituted 4-, 5-, 6- or 7- membered saturated, or unsaturated, heterocyclic group containing at least one N (but which may 5 also contain one or more O or S atoms); het3 represents an optionally substituted 4-, 5-, 6- or 7- membered saturated, or unsaturated, heterocyclic group containing at least one O (but which may also contain one or mare N or S atoms); at each occurrence R 6 independently represents H 1 C 1 -C 6 alkyl optionally substituted by Y, =(CH 2 ) g [C 3 -C 8 cycloalkyl], phenyl, benzyl, pyridyl or pyrimidyl; a and b independently represent 0 or 1; c,, d, a end g independently represent 0, 1, 2, 3 or 4; . f índeperldently represents 1, 2, 3 or 4; provided that: (i) a + b cannot equal 0; and províded,that,when R 1 represents -(CH 2 ) c -Z-(CH 2 ) d -W and W represents.NR 4 R 5 or any N linked heterocyclic, group then d must not be, 0 or 1; and (iii), provided that when R 2 represents a phenyl group substituted by a group of, formula -(CH 2 ) e OR 3 , -(CH 2 ) e -OCOR 3 or -(CH 2 ) e ,OCOR 3 ;or het 1 ,and/or het 2 are substituted by a group of formula -(CH 2 ) e OR 3 , (CH 2 ),-CO 2 R 3 or -(CH 2 ) e OCOR 3 ; or when R 7 represents -OR 3 or -(CH 2 ) f -0-(CH 2 ) e -R 3 and e is 0; or when W represents a phenyl group substituted with -OR 3 or - C0 2 R 3 and R 3 represents an alkyl group substituted with Y, and Y represents NR 4 R 5 or an N-Finked het 3 ; then, R 3 , must,represent,C 2 -C 6 alkyl substituted with. Y. are useful in the treatment of dysmenorrhoea.
    • 式(I)化合物,其药学上可接受的盐或溶剂化物,其中R'表示C 1-6烷基, - (CH 2)c - [C 3 -C 8环烷基] - , - (CH 2)C-W或 - ( CH2)CZ-(CH 2)一页; W表示C1-C6烷基,C1-C6烷氧基,-CO2 [C1-C6烷基],-CONR4R5,任选取代的苯基,NR4R5,het2, 或het <3>; Z表示O或S(O)g; g表示0,1或2; R 2表示苯基,任选地与可含有一个或多个选自N,O或S的杂原子的5-或6-元芳基或杂环基稠合; 苯基和任选稠合基团任选被取代; 环A表示含有至少一个N的4-,5-或6-元饱和杂环基; 环B表示苯基或het 1,每个基团任选被取代; R 7独立地表示H 1 C 1 -C 6烷基,OR 3, - (CH 2)e -R 3或 - (CH 2)f -O-(CH 2)e -R 3; 在每次出现时,R 3独立地表示任选被Y, - (CH 2)g [C 3 -C 8环烷基],苯基,苄基,吡啶基或嘧啶基取代的H 1 C 1 -C 6烷基; 在每次出现时,R 4和R 5独立地表示H 1 C 1 -C 6烷基(任选被C 1 -C 6烷氧基取代),(CH 2)g CO 2 - [C 1 -C 6烷基],-SO 2 Me, - (CH 2) C 3 -C 8环烷基],SO 2 Me,苯基,苄基,吡啶基或嘧啶基; 或R 4和R 5与它们所连接的N原子一起表示3至8个原子的杂环基; Y独立地表示苯基,NR4R5或het4,苯基任选被取代; 表示含有至少一个N(但也可含有一个或多个O或S原子)的4-,5-或6-元饱和或不饱和杂环基; het 2和het 4代表任选被取代的含有至少一个N(但也可以含有一个或多个O或S的N,R 5,R 6, 原子); het3表示含有至少一个O(但也可含有一个或多个N或S原子)的任选取代的4-,5-,6-或7-元饱和或不饱和杂环基; 在每次出现时,R 6独立地表示任选被Y,=(CH 2)g [C 3 -C 8环烷基],苯基,苄基,吡啶基或嘧啶基取代的H 1 C 1 -C 6烷基; a和b独立地表示0或1; c,d,末端g独立地表示0,1,2,3或4; 。 f,并且代表1,2,3或4; 条件是:(i)a + b不能等于0; 并证明当R 1表示 - (CH 2)c